The importance of molecular monitoring in acute promyelocytic leukaemia

This publication has 65 references indexed in Scilit:

• All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol
  Blood, 2002
• Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to thePML-RARαisoforms: a study of the PETHEMA group
  British Journal of Haematology, 2001
• The Signal Transducer and Activator of Transcription STAT5b Gene Is a New Partner of Retinoic Acid Receptor in Acute Promyelocytic-Like Leukaemia
  Human Molecular Genetics, 1999
• Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARα fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient
  Oncogene, 1999
• Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide
  New England Journal of Medicine, 1998
• Fusion of retinoic acid receptor α to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia
  Nature Genetics, 1997
• Absence of detectable PML-RARα fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia
  Bone Marrow Transplantation, 1997
• Quantification of PML‐RARα transcripts in acute promyelocytic leukaemia: explanation for the lack of sensitivity of RT‐PCR for the detection of minimal residual disease and induction of the leukaemia‐specific mRNA by alpha interferon
  British Journal of Haematology, 1996
• Acute promyelocytic leukemia: From clinic to molecular biology
  The International Journal of Cell Cloning, 1995
• Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia
  The Lancet, 1992